Malaria
Conditions
Interventions
Mefloquine
Sulphadozine Pyrimethamine Combination
Sponsors
Nigerian Institute of Medical Research
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: A. HIV POSITIVE POPULATION 1.HIV positive pregnant women 2. Above 13wks gestational age 3. Afebrile at the time of recruitment 4.Not sensitive to sulphadozine 5. Not sensitive to standard ITN 6.Not sensitive to mefloquine B. HIV NEGATIVE POPULATION 1.HIV negative pregnant women 2. Above 13wks gestational age 3. Afebrile at the time of recruitment 4.Not sensitive to sulphadozine 5. Not sensitive to mefloquine 6. Not sensitive to standard ITN
Exclusion criteria
Exclusion criteria: A. HIV POSITIVE POPULATION 1. SCD IN PREGNANCY 2. Known febrile illness in the Index pregnancy 3. Known sensitivity to sulphadozine/pyrimethamine combination 4. Known sensitive to mefloquine B. HIV NEGATIVE POPULATION 1. SCD IN PREGNANCY 2. Known febrile illness in the Index pregnancy 3. Known sensitivity to sulphadozine/pyrimethamine 4. Known sensitivity to mefloquine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PRIMARY OUTCOME MEASURES: 1.Placenta parasitaemia 2.Number of episodes of febrile illness associated with a positive malaria parasitaemia 3.Peripheral blood parasitaemia, demonstrable in the third trimester. 4.Number of cases of SP resistance 5.Number of cases of Mefloquine resistance | — |
Secondary
| Measure | Time frame |
|---|---|
| SECONDARY OUTCOME MEASURES: 1. Miscarriages 2. Intra-uterine deaths 3. Hospital admissions 4. Low birth weight 5. Maternal anaemia 6. Side effects and Adverse effect profile of the interventional agents | — |
Countries
Nigeria
Contacts
Public ContactEsther Ohihoin
Research Fellow Nigerian Institute of Medical Research
Outcome results
None listed